Type 2 diabetes, thiazolidinediones, and cardiovascular risk

Publisher： Royal College of General Practitioners

ISSN： 1478-5242

Source： British Journal of General Practice, Vol.59, Iss.564, 2009-07, pp. : 520-524

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Introduction: the role of the thiazolidinediones in the cardiovascular risk management of type 2 diabetes

By Barnett A.H.

Current Medical Research and Opinion, Vol. 21, Iss. 3, 2005-03 ,pp. : 1-4

Informa Healthcare

Access to resources Recommend Favorite

Different Effects of Thiazolidinediones on Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus: Pioglitazone vs Rosiglitazone

Current Drug Safety, Vol. 5, Iss. 3, 2010-07 ,pp. : 234-244

Bentham Science Publishers

Access to resources Recommend Favorite

Coffee consumption and risk of type 2 diabetes, cardiovascular diseases, and cancer

By van Dam Rob M.

Applied Physiology, Nutrition, and Metabolism, Vol. 33, Iss. 6, 2008-12 ,pp. : 1269-1283

NRC Research Press

Access to resources Recommend Favorite

Early insulin therapy and the risk of cardiovascular disease in Type 2 diabetes

By Nicasio John McFarlane Samy I

Therapy, Vol. 2, Iss. 5, 2005-09 ,pp. : 685-688

Future Medicine

Access to resources Recommend Favorite

Can thiazolidinediones delay disease progression in type 2 diabetes?

By Leiter Lawrence A.

Current Medical Research and Opinion, Vol. 22, Iss. 6, 2006-06 ,pp. : 1193-1201

Informa Healthcare

Access to resources Recommend Favorite